Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Operationally seamless Phase 2/3 study of BIC/ LEN vs stable baseline regimen in virologically suppressed adults with HIV-1
jRCT2051230168Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bictegravir + lenacapavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Virologic failure at Week 48. Started Apr 2024; status: active, not recruiting.
02
Drugs
bictegravir + lenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2051230168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230168.